WASHINGTON, Sept. 25 /PRNewswire/ — OrbusNeich today announced
that clinical trial results highlighting the company’s Genous
Bio-engineered R stent and its endothelial progenitor cell (EPC)
capture technology across challenging patient subsets were
presented during a symposium titled “EPC Capture Technology: from
Genous to Combo” at Transcatheter Cardiovascular Therapeutics (TCT)
2010 in Washington.
Genous Bio-engineered R stent is safe and effective in
diabetic patients, elderly patients and in patients who
stopped dual antiplatelet therapy (DAPT) at 30 days and at six
months due to increased risk for bleeding or DAPT
cessation.
Professor Robbert de Winter, M.D., Ph.D., of the Academic
Medical Center in Amsterdam presented a subset analysis from the
global e-HEALING registry. The findings included:
- Twelve-month follow-up data that compared results from 339
elderly patients over the age of 80 to 4,584 patients under the age
of 80 showed that the elderly patients had significantly more risk
factors such as hypertension and acute coronary syndrome (ACS) and
presented with more complex lesions. Compared to the younger
cohort, elderly patients had higher rates of target vessel failure
(TVF) driven mainly by cardiac death. Significantly, the rate of
late stent thrombosis at 12 months in elderly patients (0.3
percent) was shown to be low and similar to that of the younger
patient group (0.2 percent).
- Twelve-month outcomes were shown to be similar between patients
who stopped DAPT at 30 days and those who continued on DAPT; the
TVF rates of the two subgroups were 6.3 percent and 6.5 percent,
respectively. The subset analysis also showed that 12-month
outcomes were similar between patients who stopped DAPT at six
months and those who continued; the TVF rates of the two subgroups
were 2.8 percent and 2.4 percent, respectiv‘/>”/>
